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ABSTRACT
Early trials for immune checkpoint inhibitors in sarcomas have delivered mixed results, and efforts to
improve outcomes now look to combinatorial strategies with novel immunotherapeutics, including
some that target macrophages. To enhance our understanding of the sarcoma immune landscape, we
quantified and characterized tumor-associated macrophage infiltration and expression of the targetable
macrophage-related immune checkpoint CD47/SIRPα across sarcoma types. We surveyed immunohis-
tochemical expression of CD68, CD163, CD47, and SIRPα in tissue microarrays of 1242 sarcoma speci-
mens (spanning 24 types). Non-translocation sarcomas, particularly undifferentiated pleomorphic
sarcoma and dedifferentiated liposarcoma, had significantly higher counts of both CD68+ and CD163
+ macrophages than translocation-associated sarcomas. Across nearly all sarcoma types, macrophages
outnumbered tumor-infiltrating lymphocytes and CD163+ (M2-like) macrophages outnumbered CD68+
(M1-like) macrophages. These findings were supported by data from The Cancer Genome Atlas, which
showed a correlation between increasing macrophage contributions to immune infiltration and several
measures of DNA damage. CD47 expression was bimodal, with most cases showing either 0% or >90%
tumor cell staining, and the highest CD47 scores were observed in chordoma, angiosarcoma, and
pleomorphic liposarcoma. SIRPα scores correlated well with CD47 expression. Given the predominance
of macrophage infiltrates over tumor-infiltrating lymphocytes, the bias toward M2-like (immunosup-
pressive) macrophage polarization, and the generally high scores for CD47 and SIRPα, macrophage-
focused immunomodulatory agents, such as CD47 or IDO-1 inhibitors, may be particularly worthwhile to
pursue in sarcoma patients, alone or in combination with lymphocyte-focused agents.
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Sarcomas are a diverse group of mesenchymal malignancies,
with over 50 biologically and clinically distinct types described
by the World Health Organization.1 Unfortunately, due to the
rarity of some sarcomas, clinical trials often lump together
different sarcoma types to improve accrual and power. This
practice may disguise real clinical responses to investigational
agents, due to the confounding presence of sarcoma types
with very different biology.
Sarcomas were the first cancers to be successfully treated
by immunotherapy (Coley’s bacterial toxins in 1891),2 leading
to great interest in the application of modern cancer immu-
notherapy to sarcomas. Several immune checkpoint inhibitors
have been investigated in sarcomas,3-5 but due to low num-
bers for any individual type, it has been difficult to glean any
conclusive findings. Trials of immune checkpoint inhibitors
in other cancers are beginning to reveal high levels of
therapeutic resistance by immune escape mechanisms, includ-
ing activation of other (untargeted) immune checkpoints.6
This is leading to the increasing use of combinatorial ther-
apeutic inhibition of two or more immune checkpoints,
including some macrophage-related checkpoints, such as the
CD47/SIRPα “don’t eat me” signal. To guide design of these
combinatorial studies, particularly in a group as heteroge-
neous as sarcomas, it is critical to have a detailed, type-
specific understanding of their immune microenvironments.
Tumor-associated macrophages can affect tumor cell pro-
liferation, stromal formation and dissolution, vascularization,
and both pro- and anti-neoplastic inflammation.7 Tumor-
associated macrophages are conventionally divided into two
simplified subgroups: M1-like (classically activated by IFNγ,
pro-inflammatory, and involved in tumor killing via comple-
ment-mediated phagocytosis),8-10 and M2-like (alternatively
activated, anti-inflammatory, and involved in tissue repair
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and resolution of inflammation).8 Prior to polarization,
macrophages first exist as M0 (uncommitted) macrophages;
cytokine stimuli then largely determine the subsequent direc-
tion of polarization.11,12 This polarization is plastic, and
macrophages can switch polarization in response to further
external stimuli including IFNγ13 and IL-10.14
High levels of tumor-associated macrophages are generally
a poor prognostic factor in most cancer types,15,16 and macro-
phages were identified in 90% (45/50) of tumors in a study of
sarcomas of various types (14 GIST, 5 synovial sarcoma, 4
leiomyosarcoma, and 1–3 cases of 18 other types),17 as well as
in both alveolar and embryonal rhabdomyosarcoma.18 In The
Cancer Genome Atlas (TCGA) study of 206 adult soft tissue
sarcomas, macrophage scores derived from gene expression
signatures19,20 were highest among dedifferentiated liposar-
coma, myxofibrosarcoma, and UPS, but lower in synovial
sarcoma. In leiomyosarcoma, two studies demonstrated an
association between higher density of CD68+ or CD163
+ macrophage infiltration and poorer clinical outcomes,21,22
perhaps explaining the poor outcomes for leiomyosarcomas in
lymphocyte-based adaptive immune checkpoint inhibitor
clinical trials.3-5,23
CD47 is a ubiquitously expressed cell-surface protein that
protects viable erythrocytes from phagocytosis, sometimes
referred to as the “don’t eat me” signal.24-30 In cancer, CD47
can be over-expressed to evade phagocyte-mediated anti-
tumor immunity via interaction with SIRPα (signal-
regulatory protein alpha), a cell-surface receptor expressed
by macrophages and dendritic cells.31 Anti-CD47 monoclonal
antibodies have impressive activity in mouse xenograft
models,32-39 leading to the opening of clinical trials targeting
the CD47/SIRPα axis. In phase 1 studies targeting CD47/
SIRPα signaling, encouraging responses were seen in both
lymphoma and advanced solid tumors.39-42 Overexpression
of CD47 has been observed across most cancers,32-36,43-45
including in osteosarcoma,46 but has never been systemati-
cally examined in soft tissue sarcomas.
In this study, we assessed a wide array of sarcomas (1242
cases, over 27 sarcoma types) to determine type-specific
expression patterns of M1-like and M2-like tumor-associated
macrophages and the CD47/SIRPα immune checkpoint, and
their associations with clinical parameters and survival.
Materials and methods
Patient tumor samples
From the University of British Columbia Genetic Pathology
Evaluation Center (Vancouver, BC, Canada), 14 formalin-
fixed, paraffin-embedded tissue microarrays (TMAs) were
included: TMA 01–003 (synovial sarcoma and differential
diagnoses, 82 cases in duplicate);47 TMA 03–008 (chondroid
tumors, 121 cases in duplicate);48 TMA 06-001E (gastroin-
testinal stromal tumors, 129 cases in duplicate);49 TMA
06–007 (myxoid liposarcomas, 69 cases in triplicate);50
TMA 09–006 (epithelioid sarcoma and differential diag-
noses, 53 cases in duplicate);51 TMA 10–004 (28 chordomas,
in duplicate); TMA 10–009 (8 alveolar soft part sarcomas, 2
alveolar rhabdomyosarcomas, 2 desmoplastic small round
cell tumors, in triplicate);51 TMA 12–004 (BCL2-positive
tumors, 35 cases in triplicate);52 TMA 12–005 (pediatric
spindle cell lesions, 134 cases in duplicate);52 TMA 12–006
(translocation-associated sarcomas, 10 cases in duplicate);52
TMA 12–010 (5 dedifferentiated liposarcomas and 5 undif-
ferentiated pleomorphic sarcomas, in duplicate);52 TMA
14–006 (4 myxoid liposarcomas, 3 myxofibrosarcomas, 3
chondrosarcomas, 1 synovial sarcoma, 1 malignant periph-
eral nerve sheath tumor, in duplicate);53 TMA 14–007 (ded-
ifferentiated liposarcomas with well-differentiated areas,
both components for 57 cases in duplicate);54 and TMA
MPNST (malignant peripheral nerve sheath tumor and dif-
ferential diagnoses, 176 cases in duplicate).55 From Mount
Sinai Hospital (New York, NY, USA), four TMAs were
included: MSH-OSa (osteosarcomas, 280 cases in duplicate);
MSH-SS (synovial sarcomas, 70 cases in duplicate); MSH-
SFT (solitary fibrous tumors, 140 cases in duplicate);56 and
MSH-UPS (74 undifferentiated pleomorphic sarcomas, 52
myxofibrosarcomas, 18 leiomyosarcomas, 13 dedifferen-
tiated liposarcomas, 9 dermatofibrosarcoma protuberans,
and differential diagnoses; 210 cases total in duplicate).
Tissue microarray preparation
All tissue specimens were derived from surgical resection speci-
mens fromMount Sinai Hospital, New York, NY (MSH TMAs),
20 centers throughout Norway (TMA 06–001), BC Children’s
Hospital (TMA 12–005), or Vancouver General Hospital,
Vancouver, BC (all other TMAs). Cores with a diameter of
1.0 mm (TMA 14–007, all MSH TMAs) or 0.6mm (all other
TMAs) were extracted from representative viable tumor tissue,
as identified by a bone and soft tissue subspecialty pathologist
(AF Lee, TO Nielsen, EG Demicco). TMAs were cut to
4-µm-thick sections, mounted to Fisherbrand™ Superfrost™
Plus charged glass slides (Thermo Fisher Scientific Inc,
Waltham, MA), and incubated for 1 h at 60°C.
Immunohistochemistry
Immunohistochemical staining was performed on serial
TMA sections, which were cut in parallel batches and pro-
cessed immediately. All antibodies were applied using the
Ventana DISCOVERY® ULTRA semi-automated staining
system (Ventana Medical Systems Inc., Tucson, AZ), as
described previously.54 Briefly, heat-induced antigen retrie-
val was performed using the standard Cell Conditioning 1
(CC1, Ventana) protocol. Slides were incubated with pri-
mary antibodies (described in Table S1) in DISCOVERY
antibody diluent (Ventana) for 2 h at room temperature.
For CD68, CD47, and SIRPα, slides were incubated for 16
min at 37°C in DISCOVERY Universal secondary antibody
(Ventana), and chromogen visualization was performed by
DAB map detection (Ventana). For CD163, slides were
incubated for 2 h at room temperature with the UltraMap
anti-mouse secondary antibody (Ventana) and visualized
using the UltraMap DAB Kit (Ventana). PDL1 staining
methodology was previously reported.57
All slides were counterstained with hematoxylin and
mounted. Digital images of immunostained tissue microarrays
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were acquired using the Olympus BLISS high-definition vir-
tual microscope and slide scanner (Olympus Life Science
Solutions: Bacus Laboratories, Lombard, IL, USA) or the
Aperio digital pathology slide scanner (Leica Biosystems,
Wetzlar, Germany).
Histological scoring
Scoring was performed by pathologists experienced in scoring
biomarkers in bone and soft tissue tumors (EG Demicco,
D Gao). All immunohistochemical markers were scored for
cytomembranous positivity. Replicate cores were scored sepa-
rately, with the pathologist blinded to replicate status and final
histological diagnosis. Macrophage biomarkers (CD68,
CD163, SIRPα) were scored by counting the number of posi-
tive-staining macrophages per TMA core (Figure 1(a,b,d))
divided by the area of the core to yield a value for
macrophages/mm2, up to 2000/mm2 (scores above this
threshold were marked as 2000/mm2). CD47 was scored as
the percentage of positive-staining sarcoma tumor cells
(Figure 1(c)). CD47 staining intensity was also scored, but
excluded from analyses due to mainly uniform (saturated)
intensity across positive samples. As previously reported,
tumor-infiltrating lymphocytes (TILs) were counted directly
from hematoxylin and eosin stained slides and similarly
expressed as an absolute count per mm2, and PDL1 was
quantitated both on tumor cells and inflammatory cells.57
TCGA data analysis
Data on relative proportions of macrophages and macrophage
subsets (M0, M1, M2) and measures of DNA damage was
extracted from published data (Thorsson et al. (2018),58
Supplemental Table 1, PanImmune Feature Matrix of Immune
Characteristics; https://www.cell.com/cms/10.1016/j.immuni.
2018.03 .023/at tachment/22b1df93-e78b-40b9-bceb
-2e69aa3f55d2/mmc2.xlsx), and analyzed according to the 6 sar-
coma types defined in the TGCA sarcoma analysis: dedifferen-
tiated liposarcoma (n = 50), myxofibrosarcoma (n = 17),
undifferentiated pleomorphic sarcoma (n = 44), leiomyosarcoma
(n = 80), malignant peripheral nerve sheath tumor (n = 5), and
synovial sarcoma (n = 10).20 Data on macrophages and polarized
subsets of macrophages are represented as a percent of the total
immune infiltrate (leukocyte fraction) in a given case and do not
reflect absolute differences between cases. DNA damagemeasures
were defined per Thorsson et al.58 as follows: Intratumoral hetero-
geneity was assessed as subclonal genome fraction less the percent
of the tumor genome not represented by the plurality clone;
Homologous recombination deficiency (HRD) score summed
three variables: (1) number of regions of>15 Mb with loss of
heterozygosity, (2) breaks between adjacent segments of >10
Mb, and (3) allelic imbalances in subtelomeric regions;
Aneuploidy score was defined as the sum total of amplified or
deleted chromosome arms. Segments altered represent the total
number of altered chromosome segments in a sample. The non-
silent mutation rate, and predicted single nucleotide and indel
neoantigens (pMHCs), were likewise taken as calculated by
Thorsson et al.58
Statistical analysis
Data analysis was performed using IBM® SPSS® statistics
software (version 26). An Independent Samples Kruskal–




Figure 1. Immunohistochemical staining of macrophage and checkpoint biomarkers in sarcoma tissues. (a) CD68 (KP1 antibody), dedifferentiated liposarcoma; (b)
CD163 (10D6), osteosarcoma; (c) CD47 (B6H12), chordoma; (d) SIRPα (A-1), dedifferentiated liposarcoma.
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differences in scoring between histological types. Categories
were compared pairwise, and significance values were
adjusted using the Bonferroni correction for multiple com-
parisons. Correlations between clinicopathologic features
and immunohistochemical scores were assessed using an
independent sample Kruskal–Wallis 1-way ANOVA,
Mann–Whitney U test, Chi-squared, Fisher exact test, or
Spearman rank correlation coefficient (rS), as appropriate.
Multiple comparisons corrections were applied for clinico-
pathological-immunoprofile correlations using the
Bonferroni method. Correlations between scores for differ-
ent biomarkers and correlation between TCGA macrophage
signatures and DNA damage, and between individual
immunohistochemical markers were assessed using the
Spearman rank correlation coefficient. In order to include
cases with very low (0) levels of infiltrating immune cells
and compare relative proportions between CD68+ macro-
phages, CD163+ macrophages, and tumor-infiltrating lym-
phocytes, the counted number of positive cells/mm2 was
increased by one for all cases prior to calculating the ratio
(adjusted CD68:TIL ratio/adjusted CD163: CD68 ratio).
Survival correlates for overall survival (OS) and progres-
sion-free survival (PFS) among all non-translocation or
translocation-associated sarcomas were evaluated using
a Cox proportional hazards multiple regression analysis to
generate hazard ratios and corresponding 95% confidence
intervals. Univariable Cox proportional hazards models
were used to assess prognostic significance of macrophage
and clinicopathologic features in individual sarcoma types.
Statistically significant differences were defined as p < .05.
Ethics
Human tissue accessions for these studies were reviewed and
approved by the British Columbia Cancer Agency and the
Mount Sinai Hospital research ethics boards.
Results
Quantification of tumor-associated macrophages in the
study set
Surgical resection specimens from 1242 sarcomas (24 histo-
types with at least 4 cases for analysis, Table 1) and 252
benign bone or soft-tissue tumors (Table S2) were available
Table 1. Clinical and histopathological characteristics of sarcoma samples used in this study.
Sarcoma Types Total cases Patients with clinical data Patients with clinical data
n n n
Translocation-Associated 403 300 FNCLCC grade
Synovial sarcoma 140 104 1 95
Solitary fibrous tumor 113 100 2 209
Myxoid liposarcoma 40 35 3 198
Dermatofibrosarcoma protuberans 33 11 Unknown/na 257
Ewing sarcoma 21 15 Neoadjuvant treatment
Alveolar rhabdomyosarcoma 10 6 None 396
LGFMS 9 8 Chemotherapy 97
Alveolar soft part sarcoma 8 4 Radiation therapy 40
Clear cell sarcoma 7 5 CTRT 16
EMC 6 4 Unknown 210
Congenital fibrosarcoma 4 4 Adjuvant treatment
Other* 12 4 None 304
Non-translocation 839 459 Chemotherapy 82
Osteosarcoma 247 162 Radiation therapy 60
GIST 129 0 CTRT 15
MPNST 77 18 Unknown 298
UPS 72 53 Overall survival
Dedifferentiated liposarcoma 62 58 Alive 437
Well differentiated liposarcoma 59 7 Died 262
Chondrosarcoma*** 62 58 Unknown 60
Myxofibrosarcoma 41 33 Progression-free survival
Chordoma 28 23 Alive, NED 288
Leiomyosarcoma 20 19 Progression/died 310
Embryonal rhabdomyosarcoma 12 8 Unknown 161
Epithelioid sarcoma 9 8
Pleomorphic liposarcoma 7 0
Angiosarcoma 4 3
Intimal sarcoma 4 3
Other** 6 6
Total 1242 759
“Sarcoma Types” column describes all cases in our dataset (N = 1242) as well as those patients for which clinical data is available (n = 759);
“Clinical Parameters” column describes only the subset of patients for which clinical data is available. Abbreviations: CTRT, chemoradiation
therapy; EMC, extraskeletal myxoid chondrosarcoma; FNCLCC, Fédération Nationale des Centers de Lutte Contre le Cancer; GIST, gastro-
intestinal stromal tumor; LGFMS, low grade fibromyxoid sarcoma; MPNST, malignant peripheral nerve sheath tumor; na, not applicable; NED,
no evidence of disease; UPS, undifferentiated pleomorphic sarcoma. *Other translocation sarcomas include types with fewer than four cases
each (mesenchymal chondrosarcoma, n = 3; angiomatoid fibrous histiocytoma, n = 2; desmoplastic small round cell sarcoma, n = 2;
epithelioid hemangioendothelioma, n = 2; sclerosing epithelioid fibrosarcoma, n = 1; malignant myoepithelioma, n = 1, phosphaturic
mesenchymal tumor, n = 1). **Other non-translocation sarcomas include adult fibrosarcoma, n = 1, sarcoma NOS, n = 4; radiation-induced
sarcoma, n = 1. ***Conventional chondrosarcoma includes four dedifferentiated chondrosarcoma.
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for evaluation. Clinical data was available for 759 sarcoma
patients (Table 1, Table S3).
We quantified tumor-associated macrophages using immuno-
histochemical markers CD68 (preferentially staining M1-like
macrophages with some M2 overlap) and CD163 (preferentially
staining M2-like macrophages). Pleomorphic sarcoma types
demonstrated the highest counts of both CD68+ and CD163
+ macrophages (Figure 2(a,b)), particularly undifferentiated pleo-
morphic sarcoma (median CD68 = 460/mm2, CD163 = 512/
mm2), dedifferentiated liposarcoma (median CD68 = 418/mm2,
CD163 = 650/mm2), myxofibrosarcoma (median CD68 = 361/
mm2, CD163 = 299/mm2), and leiomyosarcoma (median
CD68 = 273/mm2, CD163 = 281/mm2). Angiosarcomas had the
highest counts for both macrophage markers (CD68 = 486/mm2,
CD163 = 1081/mm2), but these counts were scored fromonly four
patients (Figure 2(a,b)). As a group, sarcomas driven bymutations
and/or copy-number alterations (non-translocation-associated
sarcomas) had significantly higher (p < .001) macrophage counts
(median CD68 = 105/mm2, CD163 = 139/mm2) than did the
translocation-associated sarcomas (median CD68 = 36/mm2,
CD163 = 59/mm2) or benign mesenchymal tumors (median
CD68 = 18/mm2, CD163 = 38/mm2) (Figure S1A). Translocation-
associated sarcomas as a group showed no significant difference in
macrophage infiltrate counts when compared to benignmesench-
ymal tumors; however, alveolar soft part sarcomas had some of
the highest CD163+ macrophage densities, with a median count
of 404/mm2 (Figure 2(b)). Across the sample set, there was





Figure 2. Quantification of tumor-associated macrophages in sarcomas. (a) Boxplots depicting comparative counts of CD68+ macrophages across sarcoma types.
Boxes represent the first through third quartiles, vertical line indicates median, and whiskers indicate range. Extreme outliers are indicated as dots. (b) Boxplots
depicting comparative counts of CD163+ macrophages across sarcoma types. (c) Boxplots depicting comparative counts of CD68+ macrophages (white), CD163
+ macrophages (light gray), and tumor-infiltrating lymphocytes (TILs; dark gray) across sarcoma histotypes. (d) Adjusted mean ratio of CD68/TIL, based on counts of
positive-staining immune cells per mm2 tumor tissue, scored from tissue microarray cores. Error bars represent 95% confidence interval of the mean. In order to
avoid dividing by zero, all counts were adjusted by adding 1/mm2 prior to calculating ratio. (e) Boxplot illustrating proportion of tumor-immune infiltrates
represented by macrophages using mRNA expression signatures calculated on TCGA sarcoma types by Thorsson et al. (2018). Dots indicate individual tumor
specimens. Abbreviations: ASPS, Alveolar soft part sarcoma, DDLPS, dedifferentiated liposarcoma; DFSP, dermatofibrosarcoma protuberans; EMC, extraskeletal myxoid
chondrosarcoma; GIST, gastrointestinal stromal tumor; LGFMS, low grade fibromyxoid sarcoma; LMS, leiomyosarcoma; MFS, myxofibrosarcoma; MPNST, malignant
peripheral nerve sheath tumor; SS, synovial sarcoma; UPS, undifferentiated pleomorphic sarcoma.
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+macrophages (rS = 0.75, p < .001), possibly reflecting their partial
phenotypic overlap.
The degree of CD68+ macrophage infiltrates, but not
CD163+ expression, was associated with several clinicopatho-
logic features in exploratory analyses (Table S4A and S4B).
Patient age positively correlated with CD68+ macrophage
infiltrates in myxofibrosarcoma (rs = 0.49, p = .017), and
negatively correlated with CD68+ macrophage infiltrates in
solitary fibrous tumor (rs = - 0.31, p = .021). CD68+ macro-
phage infiltrates were significantly denser in high grade myx-
ofibrosarcomas compared to low-grade tumors. Macrophage
infiltrates showed inconsistent increases or decreases across
tumor types in response to neoadjuvant therapy or
recurrence.
Across nearly all sarcoma types investigated, macrophage
infiltrates outnumbered tumor-infiltrating lymphocytes
(Figure 2(c)).57 Macrophage predominance was particularly
evident among the non-translocation sarcomas, with over ten-
fold adjusted CD68:TIL ratios for chordoma, pleomorphic
liposarcoma, chondrosarcoma, undifferentiated pleomorphic
sarcoma, and angiosarcoma (Figure 2(d)). Non-translocation
sarcomas had a significantly higher adjusted CD68:TIL ratio
(mean: 6.7, 95% CI: 5.3–8.0) than was observed among the
translocation-associated sarcomas (mean: 1.8, 95% CI:
1.3–2.3)(p < .001, Figure S1B).
We compared our immunohistochemical quantitation of
macrophage density with the macrophage signatures calcu-
lated from mRNA expression data for sarcomas analyzed in
The Cancer Genome Atlas (TCGA).20 Similar to our own
findings, the TCGA data showed that the highest macrophage
signature expression was found in dedifferentiated liposar-
coma and undifferentiated pleomorphic sarcoma/myxofibro-
sarcoma. Leiomyosarcoma had the lowest macrophage
signatures among the non-translocation sarcomas evaluated,
and synovial sarcoma had the lowest overall macrophage
signature expression.20 We further investigated the relative
proportion of macrophages in sarcoma immune infiltrates –
calculated from published gene expression signatures58 – and
found that, in dedifferentiated liposarcoma, myxofibrosar-
coma, undifferentiated pleomorphic sarcoma, and malignant
peripheral nerve sheath tumor, macrophages were more likely
to comprise over half of the total immune infiltrates, while in
leiomyosarcoma and synovial sarcomas, the median contribu-
tion of macrophages to the overall immune infiltrate was less
than 50% (Figure 2(e)). These findings at the RNA level
support the validity of our immunohistochemical quantitation
and relative macrophage:TIL ratios in sarcomas.
Macrophage polarization
Using CD163 as a marker of M2-like (anti-inflammatory) macro-
phages and CD68 as a marker of M1-like (pro-inflammatory)
macrophages,59 we observed that sarcomas tend to have
a higher proportion of M2-like than M1-like macrophages
(Figure 3(a)), particularly undifferentiated pleomorphic sarcoma
(adjusted mean CD163/CD68 = 20.7, n = 65) and leiomyosar-
coma (adjusted mean CD163/CD68 = 17.4, n = 19). The M2-
like:M1-like ratio was relatively balanced in epithelioid sarcoma,
clear cell sarcoma, and both embryonal and alveolar rhabdomyo-
sarcomas (Figure 3(a)).
Similarly, within the sarcoma types analyzed by the TCGA
using gene expression signatures,58 M2 macrophages repre-
sented a larger proportion of the total immune infiltrate than
either M0- or M1- polarized macrophages (Figure S2). The
median calculated M2:(M0+ M1) ratio was higher in the non-
translocation sarcomas, ranging from 2.1 (malignant peripheral
nerve sheath tumor) to 8.6 (dedifferentiated liposarcoma),
whereas synovial sarcoma tended to have more uncommitted
M0 macrophages than M2 (median ratio M2:(M0+ M1) = 0.7).
In order to determine if macrophage infiltrates might be
related to the extent of genomic alterations in sarcoma, we
calculated Spearman rank correlation coefficients between
macrophage proportion and measures of genomic complexity
in four major non-translocation sarcoma types (dedifferen-
tiated liposarcoma (n = 50), leiomyosarcoma (n = 80), undif-
ferentiated pleomorphic sarcoma (n = 44), and
myxofibrosarcoma (n = 17)) using data from Thorsson et al.58
Overall, intratumoral heterogeneity showed a significant
positive correlation with increasing proportions of macro-
phages in the immune microenvironment (p < .05), as did
measures representing armlevel chromosomal alterations
(aneuploidy score), focal chromosomal copy number altera-
tions (number of chromosomal segments altered), and homo-
logous recombination defects. No significant changes in
relative macrophage proportion were observed based on
small nucleotide alterations (non-silent mutation rate or num-
ber of predicted neoantigens) (Figure 3(b)). Among individual
tumor types, only leiomyosarcoma showed strong correlations
between macrophage infiltrates and chromosomal alterations.
When the DNA damage scores were correlated with indivi-
dual proportions of M0-, M1-, and M2- polarized macro-
phages (Figure 3(c–e)), it was found that the increasing
proportions of macrophages in cases with higher intratumoral
heterogeneity, increased copy number alterations, or more
homologous recombination defects were attributable to
increased M2 macrophages infiltrates in these cases (Figure
3(e)); however, leiomyosarcomas also showed increased pro-
portions of M0 macrophages in cases with more frequent
copy number alterations and homologous recombination
defects (Figure 3(c)). While the M1:M2 ratio weakly corre-
lated with measures of DNA damage, these findings did not
reach significance in most sarcomas (Figure 3(f)).
Macrophage-related immune checkpoint: CD47/SIRPα
We next surveyed our sarcoma tissues for the tumor-cell-
expressed immune checkpoint CD47 and the corresponding
macrophage-expressed receptor SIRPα (Figure 4(a)). The dis-
tribution of CD47 scores was distinctly bimodal across the full
sample set, with most tissue microarray cores staining at
either 0% or ≥90% positive tumor cells (47.5% and 31.5% of
total cases, respectively; Figure 4(b)). Over half (52.5%) of the
evaluated sarcomas expressed at least focal CD47, and expres-
sion varied widely among sarcoma types. Sarcoma types with
consistently infrequent CD47 expression included undifferen-
tiated pleomorphic sarcoma (82% of cases negative for CD47),
leiomyosarcoma (78% of cases negative for CD47), and Ewing
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sarcoma (70% of cases negative for CD47) (Figure 4(b)).
Notable high expressers of CD47 included chordoma and
angiosarcoma, which demonstrated CD47 staining in all
cases, with fully 100% of neoplastic cells expressing CD47 in
82% of chordomas and 75% of angiosarcomas. Pleomorphic
and dedifferentiated liposarcomas and epithelioid sarcoma
also exhibited high proportions of CD47 staining, with
>90% of tumor cells expressing CD47 in 71%, 64%, and 63%
of samples, respectively (Figure 4(b)).
Overall, at least one SIRPα+ macrophage was identified in
31.3% of cases. The sarcoma types most commonly infiltrated
by SIRPα+ macrophages were dedifferentiated liposarcoma
(77% of cases), angiosarcoma (75%), chordoma (71%), and
well-differentiated liposarcoma (65%) (Figure 4(c)). SIRPα
infiltration was least common in low-grade fibromyxoid sar-
coma (0% of cases), chondrosarcoma (2%), epithelioid sar-
coma (13%), and synovial sarcoma (14%) (Figure 4(c)). Of







Figure 3. Macrophage polarization in sarcomas. (a) Adjusted mean ratio of CD163/CD68, based on counts of positive-staining immune cells per mm2 tumor tissue,
scored from tissue microarray cores. Error bars represent 95% confidence interval of the mean. In order to avoid dividing by zero, all values were adjusted by adding
1/mm2 prior to calculating ratio. (b-f) Heatmaps display Spearman rank correlation coefficients for pleomorphic sarcoma types between indicated macrophage
signatures (calculated as proportion of total immune infiltrate) and DNA damage measures calculated by Thorsson et al. (2018). Underlined values indicate
statistically significant correlations (p ≤ 0.05). (b) Degree of association between relative macrophage proportion of immune infiltrates and measures of DNA damage.
(c-e) Association between macrophage subsets, M0, M1, M2 with DNA damage. (f) Correlation between M1:M2 ratio and DNA damage measures. Abbreviations: ASPS,
alveolar soft part sarcoma, DDLPS, dedifferentiated liposarcoma; DFSP, dermatofibrosarcoma protuberans; EMC, extraskeletal myxoid chondrosarcoma; GIST,
gastrointestinal stromal tumor; HRD, homologous recombination deficiency; LMS, leiomyosarcoma; MFS, myxofibrosarcoma; MPNST, malignant peripheral nerve
sheath tumor; SNV & indel pMHCs, predicted neoantigens resulting from single nucleotide and insertion/deletion mutations; UPS, undifferentiated pleomorphic
sarcoma.
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on occasion was seen in tumor cells (Table S5), most notably
with 11/21 (52%) of Ewing sarcomas being positive for SIRPα
in a variable membranous to granular cytoplasmic staining
pattern. Frequent SIRPα expression in Ewing sarcoma was
confirmed using a second independent tissue microarray
showing tumor cell SIRPα expression in 18/38 (47%) of
Ewing cases.
Across all sarcomas, tumor-associated macrophage expression
of receptor SIRPα weakly correlated with tumor expression of
CD47 (rS = 0.23, p < .0001) (Figure S3A&B). Likewise, CD47 and
SIRPα expression showed weak positive correlations with both
CD68 and CD163 across all sarcomas (Figure S3B), with only
solitary fibrous tumor showing a significant negative correlation
between CD47 and both CD163 and CD68 (rS = −0.32, p = .0045,
and rS = −0.45, p < .0001, respectively; Figure S3B). SIRPα also
correlated weakly withmacrophage expression of PD-L1 across all
sarcomas (rs = 0.24, p < .0001), with significant positive correla-
tions seen in myxofibrosarcoma, osteosarcoma, dedifferentiated
liposarcoma, and synovial sarcoma (p < .04). SIRPα correlated
poorly with most clinicopathologic tumor features, with more
Figure 4. Macrophage-associated immune checkpoint CD47/SIRPα in sarcomas. (a) Schematic depicting mechanism of action of the CD47 self-recognition “don’t eat
me” immune checkpoint. Tumor-expressed CD47 ligand binds to SIRPα receptor on macrophages, inducing cytoplasmic tyrosine-phosphorylation. Phosphorylated
SIRPα recruits and activates SH2-domain-containing tyrosine phosphatases SHP-1 and SHP-2, which in turn dephosphorylate specific protein substrates – such as
F-Actin – thereby inhibiting phagocytosis. (b) Mosaic plot depicting the proportion of cases expressing CD47 (by immunohistochemistry) in 0% (white), 1–89% (gray),
or 90–100% (black) of tumor cells. Column height is proportional to the number of cases assessed. Only sarcoma types with ≥5 cases available for analysis are shown.
(c) Mosaic plot depicting the proportion of cases with at least 1 SIRPα+ macrophage (by immunohistochemistry; positive cases in gray) in any tissue microarray core.
Only sarcoma types with ≥5 cases available for analysis are shown.
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frequent positivity only in higher grade myxofibrosarcoma
(p = .039) in an exploratory analysis (Table S6A). CD47 was not
significantly correlated with specific tumor clinicopathologic fea-
tures (Table S6B).
Prognostic correlates
Multivariable Cox regression analyses were conducted for the
non-translocation and for the translocation-associated sarcomas,
taking into account patient age and immunohistochemical scores
for CD68, CD163, CD47, and SIRPα as continuous variables, and
tumor grade as low, intermediate-to-high, or unknown/not
applicable (Table S7). Among the non-translocation sarcomas,
age, grade, and lower SIRPα score were associated with worse
overall survival (OS) (p < .05), while among the translocation-
associated sarcomas only intermediate-to-high grade correlated
withworseOS (p= .04). For progression-free survival (PFS), grade
(p = .04) was associated with worse outcomes (Table S7) among
non-translocation sarcomas, while lower CD47 score was asso-
ciated with worse outcomes among translocation-associated sar-
comas (p = .03; Table S7).
Univariable Cox proportional hazards models (Figure 5)
were used to assess PFS in sarcoma types with at least 10 cases
with clinical follow-up (Table S8). While the presence of any
SIRPα+ macrophage was an adverse prognostic factor in both
synovial sarcoma and myxofibrosarcoma (Figure 5(a,b)), the
prognostic significance of CD47 and tumor-associated macro-
phages varied depending on tumor type (Figure 5(c,d)). CD47
expression was an adverse prognostic factor in osteosarcoma,
but not in solitary fibrous tumor (Figure 5(d)). That said, in
solitary fibrous tumors, high CD163 predicted inferior PFS
(Figure 5(d)), but in dedifferentiated liposarcoma high CD163
was a positive prognostic indicator (Figure 5(d)). It is possible
that the inverse correlation seen between CD47 and CD163 in
solitary fibrous tumors may account for the different effects
seen in the sarcoma type-specific contexts.
Discussion
With somewhat disappointing results emerging from immune
checkpoint blockade trials targeting the adaptive immune
response to sarcomas,3-5 newer studies are turning to
a b
dc
Figure 5. Prognostic implications of tumor-associated macrophage biomarkers in sarcomas, based on immunohistochemical staining of tissue microarrays. Kaplan–
Meier curves (a-e) show Progression-free survival (PFS) based on any SIRPα-positivity in synovial sarcoma (a) and myxofibrosarcoma (b). (c) PFS based on any CD47-
positivity in osteosarcoma. (d) Univariable Cox proportional hazards models results for sarcoma types indicated, showing all variables with p < .1. Bold font indicates
significant p < .05. Abbreviations: CT, chemotherapy; CTRT, chemoradiation therapy; DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; MFS, myxofibro-
sarcoma; RT, radiation therapy; UPS, undifferentiated pleomorphic sarcoma.
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combinations with novel immune checkpoint inhibitors, includ-
ing some that affect the innate immune response. The rational
design of these trials requires a detailed understanding of the
immune microenvironments among the diverse types of sarco-
mas. The innate and adaptive arms of the immune system work
together in concert to perform cancer immunosurveillance and
eliminate most nascent tumors. In clinically apparent tumors, the
tumor cells have subverted the innate immune response, which
includesmacrophages, to promote tumorigenesis via cytokine and
growth factor secretion. Understanding the balance between
tumor-associated macrophages and TILs may better delineate
the targetable mechanisms behind immune-evasion, specifically
for each sarcoma type. Our study provides a systematic character-
ization of tumor-associated macrophages and macrophage-
related immune checkpoint biomarker expression. To our knowl-
edge, this is the largest study to date to characterize tumor-
associated macrophages in sarcomas, and the first description of
CD47 and SIRPα expression across sarcoma types.
Our study depicts a widely variable, highly sarcoma-type-
specific expression of both CD68+ and CD163+ tumor-
associated macrophages. Tumor-associated macrophages were
most frequently observed in pleomorphic sarcomas, such as
undifferentiated pleomorphic sarcoma and dedifferentiated lipo-
sarcoma, and were most sparse in translocation-associated sarco-
mas, including synovial sarcoma, myxoid liposarcoma, clear cell
sarcoma, and low-grade fibromyxoid sarcoma. This suggests that
pleomorphic sarcoma types are somehow triggering higher levels
of phagocytic inflammation than translocation-associated sarco-
mas.Moreover, themacrophage density in pleomorphic sarcomas
exceeds that of TILs we previously published from the same tissue
set,57 suggesting that macrophages dominate the immune micro-
environment of sarcomas relative to lymphocytes.
Among macrophages, we found that M2-like (CD163+)
macrophages were the predominant phenotype, which agrees
with findings in melanoma,60 non-small cell lung cancer,61 and
colorectal cancer.59,62 The presence of large numbers of M2-like
macrophages suggests a highly immunosuppressive tumormicro-
environment, but due to the plasticity of tumor-associatedmacro-
phage polarization, this could represent anti-tumor immunity that
is suppressed-but-poised for reactivation.63 The M2-like macro-
phage predominance might be explained by tumor expression of
the CD47 self-antigen stimulating SIRPα+ macrophages, as both
were commonly seen in our sample set and were usually posi-
tively-correlated, albeit to different extents depending on tumor
type. SIRPα signaling has been shown to modulate macrophage
polarization in mice, suggesting that activation of SIRPα receptor
shifts macrophage polarization towardM2.64 High levels of CD47
expression have been shown to be an adverse prognostic factor in
several lymphomas, ovarian cancer, and glioblastoma.36 Similarly,
we found that in osteosarcoma, myxofibrosarcoma, and synovial
sarcoma, expression of either CD47 or the presence of SIRPα+
macrophages were adverse prognostic features, and moreover, we
found that in both osteosarcoma and synovial sarcoma, CD47 and
SIRPα levels correlated with higher CD68+ and CD163+ macro-
phage infiltrates, although not with each other. In contrast, high
density of CD163+macrophages showed highly variable outcome
associations, being correlated with adverse outcomes in solitary
fibrous tumor and improved outcomes in dedifferentiated lipo-
sarcoma, similar to a recent report finding positive prognostic
correlation for high CD163+ macrophages in
rhabdomyosarcoma.18 Taken together, these findings suggest
that it is the interactions between tumor cells and macrophages
that affect sarcoma behavior, rather than the degree of macro-
phage infiltration alone.
In pre-clinical trials, anti-CD47/SIRPα blockade has shown an
anti-tumor effect in a variety of human malignancies via de-
repression of macrophage phagocytosis of tumor cells,65,66
which in turn promotes the display of tumor neoantigens on
antigen-presenting cells, helping to enhance the adaptive anti-
tumor response.67 Moreover, SIRPα has been reported to be
expressed on tumor cells in some cases of renal cell carcinoma
andmelanoma, and in these tumors, SIRPα/CD47 blockade using
an anti SIRPα antibody may also directly induce cellular phago-
cytosis via opsonization.66 Early clinical trials with CD47/SIRPα
axis inhibitors have shown promising activity in B-cell lymphoma
and some solid tumors.40-42,66 Our findings, demonstrating fre-
quent expression of CD47 in many sarcomas, suggest that target-
ing the CD47/SIRPα axis in these tumors may be worthwhile, for
example, in chordoma and dedifferentiated liposarcoma.
However, it should be noted that some relatively common sar-
coma types (including leiomyosarcoma, undifferentiated pleo-
morphic sarcoma, and Ewing sarcoma) expressed CD47
infrequently, reiterating the potential for false-negative results
when trials lump together different soft tissue sarcomas.
Moreover, Ewing sarcoma cells expressed SIRPα in approximately
50% of cases, suggesting that this receptor may serve an alternate
function in Ewing sarcoma and raising the possibility that CD47-
blockade may have different effects in this context, although
directly targeting SIRPα could be considered, as suggested by
Yanagita et al. (2017).66
Our findings have significant limitations. Small numbers
were available of some sarcoma types, and tissue microarray
specimens do not take into account intratumoral heterogeneity
or immune infiltrates near the tumor margins. However, tissue
microarrays represent diagnostic core needle biopsy specimens
reasonably well68 and infiltrates were measured by cells/mm2 to
reflect this. Disagreement exists regarding the immunohisto-
chemical identification of M1-like versus M2-like macrophages.
Some studies choose to define CD68 as a general macrophage
marker, back-calculating M1 macrophages as CD68 minus
CD163.60,69 However, others have shown that CD68 tends to
underestimate the total macrophage count.70 In our sample set,
CD68 scores were lower than CD163 scores, indicating that
CD68 was not staining all macrophages. We therefore defined
CD68 as staining M1-like macrophages, although we recognize
that this represents an imperfect, simplified model.
In order to provide further support for our observations, we
used detailed RNA expression data from TCGA to model macro-
phage expression signatures. Deconvolution algorithms, such as
CIBERSORT (used in the analysis of immune subtypes across all
TCGA tumors)71 attempt to extract proportionate cell popula-
tions based on known gene signatures.While this approach has its
own limitations, we found that in general the RNAdata supported
our immunohistochemical findings, showing that macrophages
comprised a median of 56% of the immune cell infiltrates among
leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofi-
brosarcoma, and dedifferentiated liposarcoma, with a median
macrophage:lymphocyte ratio of 1.7,58 and that M2 macrophages
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represented a larger component of the immune infiltrate than
either M0 or M1.
We noted an association between measures of DNA damage
and the composition of immune infiltrates. The relative macro-
phage fraction seen in sarcomas correlated with increased intra-
tumoral heterogeneity, aneuploidy score, focal chromosomal copy
number alterations, and homologous recombination defects (with
the strongest associations seen in leiomyosarcoma). A possible
explanation for this association could be that DNA damage can
upregulate the expression of damage-associated molecular pat-
terns (DAMPs), which promote inflammation, particularly from
macrophages72 and, more specifically, M2-polarized
macrophages.73,74 Alternatively, while rapidly-growing tumors
accumulate DNA damage, they also outgrow their blood supply,
leaving behind necrotic tissue, which in turn attractsmacrophages.
In conclusion, we present the largest study to date of tumor-
associated macrophage biomarkers in sarcomas. We observe
a very high density of tumor-associated macrophages relative to
tumor-infiltrating lymphocytes, and that these are predominately
M2-like. We also observed frequent expression of the innate
immunity checkpoint CD47 – particularly among angiosarcoma,
chordoma, pleomorphic and dedifferentiated liposarcoma, and
epithelioid sarcoma – suggesting that these sarcoma subtypes are
most worthy candidates for anti-CD47 therapies, possibly in
combination with adaptive immune checkpoint inhibition strate-
gies, which are already providing evidence of activity in some of
these sarcoma subtypes.
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